153
Participants
Start Date
September 6, 2021
Primary Completion Date
July 31, 2024
Study Completion Date
July 31, 2025
EOS-448
Anti-TIGIT monoclonal antibody
pembrolizumab
Anti-PD-1 monoclonal antibody
inupadenant
A2A receptor antagonist
Dostarlimab
Anti-PD-1 monoclonal antibody
SOC chemotherapies
SOC chemotherapies in 1L mNSCLC
Cliniques universitaires St Luc-UCL, Brussels
GZA Ziekenhuizen campus Sint-Augustinus, Antwerp
UZ Leuven, Leuven
Jessa Ziekenhuis, Hasselt
CHU Helora, Mons
FPO-IRCCS Candiolo Cancer Insitute, Candiolo
CHU Caen, Caen
IDB Center-Istituto Clinico Humanitas (IRCCS), Rozzano
Centre Georges Francois Leclerc, Dijon
Hospital Universitario de Jaen, Jaén
Universita degli Studi di Pavia - Fondazione IRCCS Policlinico San Matteo, Pavia
Hospital Clinico San Carlos, Madrid
Hospital Universitario Fundación Jiménez Díaz - START Madrid, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Quirón Málaga, Málaga
Hospital Universitario de Navarra, Pamplona
Hôpital Saint André, Bordeaux
Hospital Universitario Virgen Macarena, Seville
Institut de Cancérologie de l'Ouest, Nantes
Fundacion Instituto Valenciano de Oncologia (IVO), Valencia
Consorci Hospital Gral Univ Valencia, Valencia
Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur), Valencia
AUSL Della Romagna - Ospedale S. Maria delle Croci, Ravenna
Hospital Universitario Miguel Servet, Zaragoza
Institut de Cancerologie Lorraine (ICL), Nancy
Centre Oscar Lambret, Lille
ICANS, Strasbourg
Centre Léon Bérard, Lyon
Clinique Victor Hugo, Le Mans
Pitié Salpêtrière, Paris
CHU de POITIERS, Poitiers
University of California San Diego, San Diego
Hackensack University Medical Center, Bergen
Centre Antoine Lacassagne, Nice
Hospital Althaia Xarxa Assitencial de Manresa, Manresa
Hospital Universitario de Badajoz, Badajoz
Vall d'Hebron, Barcelona
Royal Marsden Hospital (Sutton location), Sutton
Addenbrooke's Hospital, Cambridge
Royal Marsden Hospital (London location), London
Hammersmith Hospital, London
Nottingham City Hospital, Nottingham
Collaborators (2)
GlaxoSmithKline
INDUSTRY
iTeos Therapeutics
INDUSTRY
iTeos Belgium SA
INDUSTRY